{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:35:12Z","timestamp":1789684512567,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Calcific Uremic Arteriolopathy (CUA) is a rare disease, causing painful skin ulcers in patients with end stage renal disease. Recommendations for CUA management and treatment are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study on CUA cases identified in western France, in order to describe its management and outcome in average clinical practices. Selection was based on the Hayashi diagnosis criteria (2013) extended to patients with eGFR &lt;\u200930\u2009mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      . Dialyzed CUA cases were compared with 2 controls, matched for age, gender, region of treatment and time period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-nine CUA cases were identified between 2006 and 2016, including 19 non dialyzed and 70 dialyzed patients. Females with obesity (55.1%) were predominant. Bone mineral disease abnormalities, inflammation and malnutrition (weight loss, serum albumin decrease) preceded CUA onset for 6\u2009months. The multimodal treatment strategy included wound care (98.9%), antibiotherapy (77.5%), discontinuation of Vitamin K antagonists (VKA) (70.8%) and intravenous sodium thiosulfate (65.2%). 40.4% of the patients died within the year after lesion onset, mainly under palliative care. Surgical debridement, distal CUA, localization to the lower limbs and non calcium-based phosphate binders were associated with better survival. Risks factors of developing CUA among dialysis patients were obesity, VKA, weight loss, serum albumin decrease or high serum phosphate in the 6 months before lesion onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CUA involved mainly obese patients under VKA. Malnutrition and inflammation preceded the onset of skin lesions and could be warning signs among dialysis patients at risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02854046\">NCT02854046<\/jats:ext-link>\n                      , registered August 3, 2016.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-01722-y","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T09:02:49Z","timestamp":1582707769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3391-6333","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Gaisne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"P\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victorio","family":"Menoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryvonne","family":"Hourmant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Larmet-Burgeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"issue":"1","key":"1722_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.ajkd.2015.01.034","volume":"66","author":"SU Nigwekar","year":"2015","unstructured":"Nigwekar SU, Kroshinksy D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis Off J Natl Kidney Found. 2015;66(1):133\u201346.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"1","key":"1722_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1046\/j.1523-1755.2001.00803.x","volume":"60","author":"AR Mazhar","year":"2001","unstructured":"Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60(1):324\u201332.","journal-title":"Kidney Int"},{"issue":"6","key":"1722_CR3","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1046\/j.1523-1755.2002.00375.x","volume":"61","author":"A Fine","year":"2002","unstructured":"Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61(6):2210\u20137.","journal-title":"Kidney Int"},{"issue":"11","key":"1722_CR4","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1681\/ASN.2015091065","volume":"27","author":"SU Nigwekar","year":"2016","unstructured":"Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic Arteriolopathy risk factors. J Am Soc Nephrol. 2016;27(11):3421\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1722_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/ndt\/gfw025","volume":"31","author":"VM Brandenburg","year":"2016","unstructured":"Brandenburg VM, Evenepoel P, Floege J, et al. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrol Dial Transplant. 2016;31(8):1211\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"18","key":"1722_CR6","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMra1505292","volume":"378","author":"SU Nigwekar","year":"2018","unstructured":"Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;378(18):1704\u201314.","journal-title":"N Engl J Med"},{"issue":"11","key":"1722_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/DAD.0000000000000824","volume":"39","author":"TY Chen","year":"2017","unstructured":"Chen TY, Lehman JS, Gibson LE, et al. Histopathology of Calciphylaxis: cohort study with clinical correlations. Am J Dermatopathol. 2017;39(11):795.","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"1722_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s10157-013-0782-z","volume":"17","author":"M Hayashi","year":"2013","unstructured":"Hayashi M. Calciphylaxis: diagnosis and clinical features. Clin Exp Nephrol. 2013;17(4):498\u2013503.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"1722_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.kint.2018.03.016","volume":"94","author":"CL Ellis","year":"2018","unstructured":"Ellis CL, O\u2019Neill WC. Questionable specificity of histologic findings in calcific uremic arteriolopathy. Kidney Int. 2018;94(2):390\u20135.","journal-title":"Kidney Int"},{"issue":"4","key":"1722_CR10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/ndt\/gfr658","volume":"27","author":"M Hayashi","year":"2012","unstructured":"Hayashi M, Takamatsu I, Kanno Y, et al. A case\u2013control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580\u20134.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1722_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000348806","volume":"37","author":"SU Nigwekar","year":"2013","unstructured":"Nigwekar SU, Bhan I, Turchin A, et al. Statin use and calcific uremic Arteriolopathy: a matched case-control study. Am J Nephrol. 2013;37(4):325\u201332.","journal-title":"Am J Nephrol"},{"issue":"6","key":"1722_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1681\/ASN.2016060651","volume":"28","author":"SU Nigwekar","year":"2017","unstructured":"Nigwekar SU, Bloch DB, Nazarian RM, et al. Vitamin K-dependent carboxylation of matrix Gla protein influences the risk of Calciphylaxis. J Am Soc Nephrol. 2017;28(6):1717\u201322.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1722_CR13","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1083\/jcb.102.5.1971","volume":"102","author":"D Stern","year":"1986","unstructured":"Stern D. Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. J Cell Biol. 1986;102(5):1971\u20138.","journal-title":"J Cell Biol"},{"issue":"10","key":"1722_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.mayocp.2016.06.026","volume":"91","author":"RA El-Azhary","year":"2016","unstructured":"El-Azhary RA, Patzelt MT, McBane RD, et al. Calciphylaxis: a disease of Pannicular thrombosis. Mayo Clin Proc. 2016;91(10):1395\u2013402.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1722_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2017.4920","volume":"154","author":"AS Dobry","year":"2018","unstructured":"Dobry AS, Ko LN, St John J, et al. Association between Hypercoagulable conditions and Calciphylaxis in patients with renal disease: a case-control study. JAMA Dermatol. 2018;154(2):182.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1722_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/ijd.13685","volume":"56","author":"BJ King","year":"2017","unstructured":"King BJ, El-Azhary RA, McEvoy MT, et al. Direct oral anticoagulant medications in calciphylaxis. Int J Dermatol. 2017;56(10):1065\u201370.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1722_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000491881","volume":"48","author":"AC Garza-Mayers","year":"2018","unstructured":"Garza-Mayers AC, Shah R, Sykes DB, et al. The successful use of Apixaban in Dialysis patients with Calciphylaxis who require anticoagulation: a retrospective analysis. Am J Nephrol. 2018;48(3):168\u201371.","journal-title":"Am J Nephrol"},{"issue":"9","key":"1722_CR18","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.mayocp.2018.06.001","volume":"93","author":"R Bajaj","year":"2018","unstructured":"Bajaj R, Courbebaisse M, Kroshinsky D, et al. Calciphylaxis in patients with Normal renal function: a case series and systematic review. Mayo Clin Proc. 2018;93(9):1202\u201312.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"1722_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.2215\/CJN.00530108","volume":"3","author":"SU Nigwekar","year":"2008","unstructured":"Nigwekar SU, Wolf M, Sterns RH, et al. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3(4):1139\u201343.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1722_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jama.2013.7833","volume":"310","author":"JP Reis","year":"2013","unstructured":"Reis JP, Loria CM, Lewis CE, et al. Association between duration of overall and abdominal obesity beginning in young adulthood and coronary artery calcification in middle age. JAMA. 2013;310(3):280\u20138.","journal-title":"JAMA"},{"issue":"3","key":"1722_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamadermatol.2016.4821","volume":"153","author":"WY-H Yu","year":"2017","unstructured":"Yu WY-H, Bhutani T, Kornik R, et al. Warfarin-associated nonuremic Calciphylaxis. JAMA Dermatol. 2017;153(3):309\u201314.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1722_CR22","first-page":"126","volume":"32","author":"VM Brandenburg","year":"2017","unstructured":"Brandenburg VM, Kramann R, Rothe H, et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2017;32(1):126\u201332.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1722_CR23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.2215\/CJN.09880912","volume":"8","author":"SU Nigwekar","year":"2013","unstructured":"Nigwekar SU, Brunelli SM, Meade D, et al. Sodium thiosulfate therapy for calcific uremic Arteriolopathy. Clin J Am Soc Nephrol. 2013;8(7):1162\u201370.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1722_CR24","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/ndt\/gfs548","volume":"28","author":"E Zitt","year":"2013","unstructured":"Zitt E, K\u00f6nig M, Vychytil A, et al. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant. 2013;28(5):1232\u201340.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1722_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaad.2006.08.065","volume":"56","author":"RH Weenig","year":"2007","unstructured":"Weenig RH, Sewell LD, Davis MDP, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569\u201379.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1722_CR26","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.mayocp.2016.06.025","volume":"91","author":"JT McCarthy","year":"2016","unstructured":"McCarthy JT, El-Azhary RA, Patzelt MT, et al. Survival, risk factors, and effect of treatment in 101 patients with Calciphylaxis. Mayo Clin Proc. 2016;91(10):1384\u201394.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1722_CR27","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.surg.2009.09.022","volume":"146","author":"G Lal","year":"2009","unstructured":"Lal G, Nowell AG, Liao J, et al. Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery. 2009;146(6):1028\u201334.","journal-title":"Surgery"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01722-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-01722-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01722-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T19:14:29Z","timestamp":1614194069000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01722-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01722-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"assertion":[{"value":"27 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the Nantes University Hospital (Groupe Nantais d\u2019Etudes dans le Domaine de la Sant\u00e9 (GNEDS)) on 20th January 2016. A written consent form was given to each patient, except for deceased patients and loss of follow-up patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VM reports receiving grant support from Meditor and consulting fees from Astellas. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}